Literature DB >> 16506050

Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.

Ukihide Tateishi1, Umio Yamaguchi, Kunihiko Seki, Takashi Terauchi, Yasuaki Arai, Tadashi Hasegawa.   

Abstract

PURPOSE: This study was conducted to investigate whether( 18)F-fluorodeoxyglucose (FDG) uptake, quantified by positron emission tomography (PET), correlates with histological variables including tumour grade, cell proliferation, cell cycle control integrity and glucose metabolism in patients with bone and soft tissue sarcomas.
METHODS: Eighty-two patients clinically suspected of having a bone or soft tissue sarcoma underwent FDG PET within 1 week prior to operation and 63 patients (mean age 48 years, range 18-74 years) were enrolled in the complete analysis. We excluded 17 patients with pathologically confirmed benign tumours and two patients with uncontrolled diabetes or concomitant malignancy from data analysis. Maximum and average standardised uptake values (SUVs) of the primary lesion were compared with histological variables including tumour differentiation, the presence of necrosis, MIB-1 score, mitotic score, p53 overexpression, MIB-1 grade, mitotic grade and GLUT-1 expression.
RESULTS: Significant correlations were found between maximal and mean SUVs and MIB-1 grade, mitotic grade, MIB-1 score, tumour differentiation and mitotic score. The mean and maximal SUVs were significantly higher in tumours with p53 overexpression than in those without p53 overexpression (p<0.0001). GLUT-1-positive tumours had significantly higher mean (6.5+/-4.2 vs 1.1+/-0.2, p=0.006) and maximal SUVs (8.8+/-5.4 vs 1.7+/-0.5, p=0.005) than the GLUT-1-negative tumours. GLUT-1 intensity correlated positively with both mean (r=0.500, p<0.0001) and maximal SUVs (r=0.509, p<0.0001). Mu ltiple linear regression analysis showed a significant correlation between maximal SUV and MIB-1 grade (p<0.0001).
CONCLUSION: The enhanced glucose metabolism, as determined by SUV, is a strong index of tumour grade in bone and soft tissue sarcomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16506050     DOI: 10.1007/s00259-005-0044-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  28 in total

1.  Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1.

Authors:  S Ito; T Nemoto; S Satoh; H Sekihara; Y Seyama; S Kubota
Journal:  Arch Biochem Biophys       Date:  2000-01-01       Impact factor: 4.013

2.  Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.

Authors:  Miriam A Bredella; Gary R Caputo; Lynne S Steinbach
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

3.  P53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness.

Authors:  G Toffoli; C Doglioni; C Cernigoi; S Frustaci; T Perin; B Canal; M Boiocchi
Journal:  Ann Oncol       Date:  1994-02       Impact factor: 32.976

4.  18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.

Authors:  Tzu-Chen Yen; Lai-Chu See; Chyong-Huey Lai; Chou Wu Yah-Huei; Koon-Kwan Ng; Shih-Ya Ma; Wuu-Jyh Lin; Jenn-Tzong Chen; Wen-Jie Chen; Chiung-Ru Lai; Swei Hsueh
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

5.  The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.

Authors:  J Costa; R A Wesley; E Glatstein; S A Rosenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

Review 6.  The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.

Authors:  E Bastiaannet; H Groen; P L Jager; D C P Cobben; W T A van der Graaf; W Vaalburg; H J Hoekstra
Journal:  Cancer Treat Rev       Date:  2004-02       Impact factor: 12.111

7.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Authors:  E Latres; M Drobnjak; D Pollack; M R Oliva; M Ramos; M Karpeh; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

8.  Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.

Authors:  Hiroyuki Kato; Junko Takita; Tatsuya Miyazaki; Masanobu Nakajima; Yasuyuki Fukai; Norihiro Masuda; Minoru Fukuchi; Ryokuhei Manda; Hitoshi Ojima; Katsuhiko Tsukada; Hiroyuki Kuwano; Noboru Oriuchi; Keigo Endo
Journal:  Anticancer Res       Date:  2003 Jul-Aug       Impact factor: 2.480

9.  Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer.

Authors:  J K Chung; Y J Lee; S K Kim; J M Jeong; D S Lee; M C Lee
Journal:  Nucl Med Commun       Date:  2004-01       Impact factor: 1.690

10.  Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning.

Authors:  Sylvain Beaulieu; Brian Rubin; David Djang; Ernest Conrad; Eric Turcotte; Janet F Eary
Journal:  AJR Am J Roentgenol       Date:  2004-04       Impact factor: 3.959

View more
  26 in total

1.  The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.

Authors:  Andrea Angelini; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giulia Polverari; Giulia Trovarelli; Emanuela Palmerini; Stefano Ferrari; Stefano Fanti; Pietro Ruggieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

2.  Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.

Authors:  Hans-Richard Demel; Benedikt Feuerecker; Guido Piontek; Christof Seidl; Birgit Blechert; Anja Pickhard; Markus Essler
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

3.  Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma.

Authors:  Jian Fan; Jiong Mei; Ming-Zhu Zhang; Feng Yuan; Shan-Zhu Li; Guang-Rong Yu; Long-Hui Chen; Qian Tang; Cory J Xian
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

4.  Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.

Authors:  Sewha Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2012-05-27

5.  Impact of cell-proliferation-associated gene expression on 2-deoxy-2-[(18)f]fluoro-D-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors.

Authors:  Ludwig G Strauss; Dirk Koczan; Sven Klippel; Leyun Pan; Caixia Cheng; Uwe Haberkorn; Stefan Willis; Antonia Dimitrakopoulou-Strauss
Journal:  Mol Imaging Biol       Date:  2010-12-10       Impact factor: 3.488

6.  Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.

Authors:  Wolfgang P Fendler; Rebecca P Chalkidis; Harun Ilhan; Thomas Knösel; Ken Herrmann; Rolf D Issels; Peter Bartenstein; Clemens C Cyran; Lars H Lindner; Marcus Hacker
Journal:  Eur Radiol       Date:  2015-02-19       Impact factor: 5.315

7.  Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Authors:  T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-03       Impact factor: 3.825

8.  Metabolic phenotypes in triple-negative breast cancer.

Authors:  Sewha Kim; Do Hee Kim; Woo-Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2013-02-27

9.  Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma.

Authors:  Punit Sharma; Bangkim Chandra Khangembam; K C Sudhir Suman; Harmandeep Singh; Sishir Rastogi; Shah Alam Khan; Sameer Bakhshi; Sanjay Thulkar; Chandrasekhar Bal; Arun Malhotra; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-05       Impact factor: 9.236

10.  Use of 18F-fluorodeoxyglucose positron emission tomography in patients with rare head and neck cancers.

Authors:  Jong-Lyel Roh; Byoung Jae Moon; Jae Seung Kim; Jeong Hyun Lee; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Bong-Jae Lee; Sang Yoon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-06-20       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.